Andreesen R, Osterholz J, Luckenbach A, Costabel U, Schulz A, Speth V, Munder PG, Löhr GW (1984) Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J Natl Cancer Inst 72:53–58
Google Scholar
Berdel WE, Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Modest EJ, Rastetter J (1990) In vitro studies in the cross resistance pattern of membrane active lipids (abstract 11.24.03). J Cancer Res Clin Oncol 116:993
Google Scholar
Berger MR, Eibl H (1992) Erucylphosphocholine is a second generation alkylphosphocholine (abstract 2483). Proc Am Assoc Cancer Res 33:416
Google Scholar
Eibl H, Unger C (1987) Phospholipide als Antitumormittel: Möglichkeiten einer selektiven Therapie. In: Unger C, Eibl H, Nagel GA (eds) Die Zellmembran als Angriffspunkt der Tumortherapie. Zuckerschwerdt, München, pp 1–18
Google Scholar
Fleer EAM, Unger C, Kim DJ, Eibl H (1987) Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids 22:856–861
Google Scholar
Geilen CC, Haase R, Buchner K, Wieder T, Hucho F, Reutter W (1991) The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonizes phorbol ester-stimulated cell proliferation. Eur J Cancer 27:1650–1653
Google Scholar
Geilen CC, Wieder T, Reutter W (1992) Hexadecylphosphocholine inhibits translocation of CTP: phosphocholine cytidylyltransferase in Madine-Darby canine kidney cells. J Biol Chem (in press)
Grunicke HH, Überall F (1992) Protein kinase C — modulation. Semin Oncol (in press)
Haase R, Geilen CC, Reutter W (1990) Comparison of the effects of the antineoplastic agent hexadecylphosphocholine and of different modulators. of PKC on cell proliferation (abstract). Naunyn-Schmiedeberg's Arch Pharmacol 342:A42
Google Scholar
Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18506). Eur J Cancer Clin Oncol 24:1457–1461
Google Scholar
Hilgard P, Harleman JH, Voegeli R, Maurer HR, Echarti C, Unger C (1989) The antineoplastic activity of hexadecylphosphocholine (HPC) is associated with tumor cell differentiation (abstract 2310). Proc Am Assoc Cancer Res 30:580
Google Scholar
Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T (1991) Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J Cancer Res Clin Oncol 117:403–408
Google Scholar
Hilgard P, Stekar J, Voegeli R, Harleman JH (1992) Experimental therapeutic studies with miltefosine in rats and mice. In: Eibl H, Hilgard P, Unger C (eds) Progress in experimental tumor research, vol 34. S. Karger, Basel, pp 116–130
Google Scholar
Hochhuth C, Berkovic D, Eibl H, Unger C, Deonecke D (1990) Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells. J Cancer Res Clin Oncol 116:459–466
Google Scholar
Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Überall F, Grunicke HH (1988) Enhancement of the antiproliferative effect ofcis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of PKC. Int J Cancer 42:382–388
Google Scholar
Hofmann J, Überall F, Posch L, Maly K, Herrmann DBJ, Grunicke HH (1989) Synergistic enhancement of the antiproliferative activity ofcis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids 24:312–317
Google Scholar
Lassing I, Lindberg U (1985) Specific interaction between phosphatidylinositol-4,5-bisphosphate and profilactin. Nature 314:472–474
Google Scholar
Minana MD, Felipo V, Grisolia S (1990) Inhibition of protein kinase C induces differentiation in Neuro-2a cells. Proc Natl Acad Sci USA 87:4335–4339
Google Scholar
Muschiol C, Berger MR, Schuler B, Scherf HR, Garzon FT, Zeller WJ, Unger C, Eibl HJ, Schmähl D (1987) Alkylphosphocholines: toxicity and anticancer properties. Lipids 22:930–934
Google Scholar
Nooter K, Vecht B van der, Hogeweg M, Visser J, Hilgard P, Verweij J (1992) The in vitro effects of hexadecylphosphocholine on the murine hemopoietic system (abstract 26). Proceedings, 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 17–20, p. 65
Parodi MT, Varesio L, Tonini GP (1990) The specific inhibitor of protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H7), induces morphological change and cell differentiation of human neural crest-derived cell lineages. FEBS Lett 269:4–6
Google Scholar
Pignol B, Coulomb H, Chaumeron S, Maisonnet T, Vandamme B, Broquet C, Mencia-Huerta JM, Braquet P (1990) Effect of synthetic alkyllysophosphatidylcholine (ALP) on IL-1, TNF and IL-2 productions (absstract 126). Anticancer Res 10:1380
Google Scholar
Schallier DK, Brunyneel EA, Storme GA, Hilgard P, Mareel MM (1991) Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res 11:1285–1292
Google Scholar
Spruß T, Bernhardt G, Reile H, Schönenberger H, Engel J (1989) Combination therapy with platinum complexes and hexadecylphosphocholine of MXT mouse mammary adenocarcinomas (abstract TH10). J Cancer Res Clin Oncol 115:55
Google Scholar
Stekar J, Schumacher W, Nößner G, Kutscher B (1992) D-20133, a novel alkylphospholipid with high antineoplastic activity. J Cancer Res Clin Oncol [Suppl] 118:83
Google Scholar
Überall F, Oberhuber H, Maly K, Zaknum J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51:807–812
Google Scholar
Unger C, Eibl H, Nagel GA, Heyden HW von, Breiser A, Engel J, Stekar J, Peukert M, Hilgard P, Berger M (1989) Hexadecylphosphocholine in the topical treatment of skin metastases: a phase I trial. Contrib Oncol 37:219–223
Google Scholar
Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl HJ (1991) Hexadecylphosphocholine: determination of serum concentration in rats. J Lipid Mediators 3:71–78
Google Scholar
Vehmeyer K, Scheurich P, Eibl H, Unger C (1991) Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin-2. Cell Immunol 137:232–238
Google Scholar
Vehmeyer K, Eibl H, Unger C (1992) Hexadecylphosphocholine stimulates the colony-stimulating factor-dependent growth of hemopoietic progenitor cells. Exp Hematol 20:1–5
Google Scholar
Verweij J, Planting AST, Stoter G (1992) Increases in leucocyte and platelet counts induced by the ether lipid hexadecylphosphocholine (HePC) (abstract 31). Proceedings, 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 17–20, p. 66
Yanapirut P, Berger MR, Reinhardt M, Schmähl D (1991) In vitro investigations on the antineoplastic effect of hexadecylphosphocholine. Arzneimittelforschung 41:652–655
Google Scholar